
Akihiro Tanaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9414532/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Panniculitis in dermatomyositis: Two cases with antitranscriptional intermediary factorâ€1 antibody as myositisâ€specific antibody and review of the literature. Journal of Cutaneous Immunology and Allergy, 2022, 5, 88-93.	0.2	2
2	Relationship between Psoriasis and Prevalence of Cardiovascular Disease in 88 Japanese Patients. Journal of Clinical Medicine, 2021, 10, 3640.	1.0	9
3	Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells. Arthritis Research and Therapy, 2020, 22, 264.	1.6	11
4	Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. Blood Advances, 2020, 4, 3572-3585.	2.5	13
5	FRI0550â€CAN CYTOKINE GENE POLYMORPHISMS BE USEFUL FOR THE THERAPEUTIC CHOICE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS?. Annals of the Rheumatic Diseases, 2020, 79, 876.2-877.	0.5	0
6	AB0141â€MYCOPHENOLATE MOFETIL, INHIBITOR OF INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE, REGULATES DIFFERENTIATION, MATURATION AND FUNCTION OF HUMAN DENDRITIC CELL SUBSETS. Annals of the Rheumatic Diseases, 2020, 79, 1370.1-1371.	0.5	0
7	Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus. Lupus, 2019, 28, 1120-1127.	0.8	23
8	<p>The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells</p> . Journal of Blood Medicine, 2019, Volume 10, 217-226.	0.7	9
9	Statins can suppress DCâ€mediated Th2 responses through the repression of OX40â€ligand and CCL17 expression. European Journal of Immunology, 2019, 49, 2051-2062.	1.6	13
10	IL-33 Promotes the Induction and Maintenance of Th2 Immune Responses by Enhancing the Function of OX40 Ligand. Allergology International, 2014, 63, 443-455.	1.4	90
11	Serum Interleukin 6 Before and After Therapy with Tocilizumab Is a Principal Biomarker in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 1074-1081.	1.0	80
12	A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment. Modern Rheumatology, 2011, 21, 302-304.	0.9	12